|Targets||Corticotropin-releasing factor (CRF)|
|Description||CP-316311, a pyridine derivative, has been found to be a CRF 1 receptor antagonist and was once studied as an antidepressant agent by Pfizer. IC50: 6.8 nM.|
|Synonyms||CP-316311; Pyridine, 4-(1-ethylpropoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
R-121919 is a potent orally active small-molecule Corticotropin-Releasing factor 1 (CRF1) receptor antagonist for the treatment of anxiety and depression, while...
Astressin is a novel potent corticotropin releasing factor (CRF) antagonist. Astressin may be a useful tool to explore functional CRF-dependent physiological pa...
CP-376395 HCl is a potent and selective CRF1 receptor antagonist with Ki values of 12 and >10000 nM for CRF1 and CRF2 receptors respectively. It attenuates CRF-...
CP-316311, a pyridine derivative, has been found to be a CRF 1 receptor antagonist and was once studied as an antidepressant agent by Pfizer. IC50: 6.8 nM.
JNJ-19567470 is a selective Corticotropin releasing factor (CRF) receptor antagonist. It is a novel target for developing anti-panic drugs. JNJ-19567470 is as e...
NBI-27914 is antagonist of the CRF1 and CRF2 recepetors (Corticotropin-releasing factor).
SSR125543 is a selective corticotropin-releasing factor 1 receptor (CRF1) antagonist with pKi value of 9.08 for native CRF1 receptor. It can prevent stress-indu...
NBI-30545 is a potent corticotropin-releasing factor-1 antagonist with proper lipophilicity (log D = 2.78) and good solubility in water (>10mg/mL), and exhibite...
NBI-34041, also called as SB 723620, is potent and high-affinity corticotropin-releasing factor receptor 1 (CRF1) receptor antagonist. NBI-34041 shows that inhi...